You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

12 Items
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Drugs Used:
topotecan (Unfunded),
May 2019
Cancer Type: Sarcoma, Ewing's, Soft Tissue     
Intent: Palliative
Feb 2018
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
  • everolimus - Metastatic renal cell carcinoma, with specific criteria
Jun 2017
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (PNET), with specific criteria
Jun 2019
Cancer Type: Lung, Neuroendocrine (Lung)     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - Treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of GI or lung origin, according to clinical criteria
May 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
ODB Limited Use
    exemestane - In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
Jun 2019
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Updated
Aug 2019
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Funding:
New Drug Funding Program
    Topotecan - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Topotecan - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Aug 2017
Cancer Type: Lung, Small Cell     
Intent: Palliative
Drugs Used:
topotecan (Unfunded)
Dec 2017
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Funding:
New Drug Funding Program
    Topotecan - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Aug 2017
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Funding:
New Drug Funding Program
    Topotecan - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Bevacizumab for Platinum-Resistant Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer
May 2019
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Funding:
New Drug Funding Program
    Topotecan - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Bevacizumab for Platinum-Resistant Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer
May 2019